GLP‑1–pathway agonists such as semaglutide and newer multi‑agonists have transformed care for obesity and diabetes, yet ...
GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...
15hon MSN
Eating 2 to 3 kiwis a day can relieve chronic constipation, according to new dietary guidelines
Do you often experience difficulty defecating? If the answer is yes, newly released recommendations may help relieve your ...
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, ...
The word “flavonoids” pops up in many discussions about food and diets but just what are they? Flavonoids (also known as ...
Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...
The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...
The global enzymes market is on a robust growth trajectory, projected to expand from an estimated USD 15.4 billion in 2025 to ...
Yang, Y. (2025) Research Progress of Nano ZnO and Its Composites in the Field of Antibacterial Technology. Journal of Biomaterials and Nanobiotechnology, 16, 31-38. doi: 10.4236/jbnb.2025.163003 .
Natural products derived from microorganisms are a promising source of new active ingredients, but are often produced only in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback